Related Experiment Videos
Dendritic cell immunotherapy for cancer: application to low-grade lymphoma and multiple myeloma
1Mater Medical Research Institute and Cancer Services, Mater Adult Hospital, South Brisbane, Queensland, Australia.dhart@mater.org.au
Abstract:
The confirmation that most cancers express one or more molecular changes, which may act as tumour-associated antigens (TAA), combined with the knowledge that T lymphocytes recognize even single amino acid differences in MHC presented peptides has stimulated renewed clinical interest in immunotherapeutic strategies. Dendritic cells (DC) are now recognized as specialist antigen-presenting cells, which initiate, direct and regulate immune responses. Recent data suggest that DC are not recruited into, or activated by, cancers and that other abnormalities in DC function are associated with malignancy, including multiple myeloma. This provides a rationale for designing immunotherapeutic strategies, which exploit DC as nature's adjuvant either in vivo or in vitro. Low-grade lymphoma and multiple myeloma are slowly progressive malignancies, which generally express a unique immunoglobulin idiotype as a potential TAA. Data from animal models and clinical studies suggest that DC-based immunotherapy strategies, applied when the patient has minimal residual disease, may improve the long-term prognosis in these diseases.
Insights
Dendritic cell (DC) immunotherapy shows promise for treating cancers like lymphoma and multiple myeloma by targeting unique tumor antigens. This approach may improve long-term patient prognosis, especially in minimal residual disease stages.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Cancers express tumor-associated antigens (TAA), recognized by T lymphocytes.
- Dendritic cells (DC) are crucial antigen-presenting cells for initiating immune responses.
- Malignancies like multiple myeloma exhibit impaired DC function, suggesting a therapeutic target.
Purpose of the Study:
- To explore the rationale for DC-based immunotherapy in malignancies.
- To investigate the potential of exploiting DC as adjuvants in cancer treatment.
- To evaluate DC-based strategies for low-grade lymphoma and multiple myeloma.
Main Methods:
- Review of existing data on cancer immunology and DC function.
- Analysis of TAA expression in specific malignancies.
- Consideration of in vivo and in vitro DC-based therapeutic approaches.
Main Results:
- DC abnormalities are associated with cancers, including multiple myeloma.
- Low-grade lymphoma and multiple myeloma express unique idiotype TAA.
- Animal models and clinical studies suggest potential benefits of DC immunotherapy.
Conclusions:
- DC-based immunotherapy offers a rationale for treating certain malignancies.
- Exploiting DC as adjuvants can enhance anti-tumor immune responses.
- DC immunotherapy in minimal residual disease may improve long-term outcomes for lymphoma and myeloma.